Navigation Links
Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High

EXTON, Pa., Nov. 25 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20. The reports assess trial and use of Stelara, obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other approved psoriasis agents.

Virtually all Dermatologists are aware of Stelara and interest in the product is high. Dermatologists view the required health care professional administration and the quarterly maintenance doing option as an advantage compared to other available biologic agents. On the downside, Dermatologists express concerns regarding the difficulty in obtaining managed care approval which has caused delays in the fulfillment of prescriptions for Stelara to date. Stelara uptake may also be somewhat blunted by the shadow of this year's withdrawal of Genentech's Raptiva related to serious adverse events. According to one respondent, "It kind of shell shocked us a little bit and we're always a bit leery about new agents."

Despite these concerns, there is strong interest in Stelara among Dermatologists. Nearly one-third of those surveyed have already prescribed the drug during the first month following launch. Among those who have yet to prescribe, 32% anticipate a product trial in the next three months. Considering the dominant market share position of Enbrel, it is not surprising that Stelara uptake is projected to have the greatest impact on Enbrel use.

The next wave of research will be conducted in January 2010 at three months post launch.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. ( provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or

All company, brand, or product names contained in this document may be trademarks of their respective holders.

Media Contact:
Jennifer Robinson

SOURCE BioTrends Research Group, Inc.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
2. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
3. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
4. Despite Recessionary Pressures, Patient and Surgeon Demand Will Drive the Joint Arthroplasty and Fixation Bone Cement Market by 7% Annually Through 2013
5. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
6. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
7. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
8. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
9. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
10. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery
11. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 /PRNewswire/ ... --> Juntendo universitetssjukhus ser potential att ... av magnetresonansbilder (MR-bilder) för patienter med ... tecknat ett forskningsavtal med SyntheticMR AB för ... kliniska forskningsprojekt på sjukhuset. Med SyMRI kan ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed ... As people age, more care is needed, especially with Alzheimer’s, dementia and other ... are being overworked. The forgotten part of this equation: 80 percent of medical ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just ... is offering customers 10% off of their purchase of lice treatment product. In addition, ... price. According to a company spokesperson. “Finding lice is a sure way to ruin ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):